Asia Pacific Biotechnology Market (2007-2010)

Published by: RNCOS

Published: Jun. 1, 2007 - 150 Pages

Table of Contents

1. Analyst View

2. Research Overview

3. Biotechnology Industry Overview

3.1 Market Overview

3.2 Venture Financing Capital

3.3 Mergers & Acquisitions

3.4 US - Growing & Leading the Market

3.5 Europe - Sustained Recovery

3.6 Asia-Pacific - Most Promising Region

4. Asia-Pacific Biotechnology Market

4.1 Introduction

4.2 Market Size

4.3 Market Segmentation

5. Asia-Pacific Biotechnology Market by Country

5.1 Japan

5.1.1 Market Overview

5.1.2 Market Segmentation

5.1.3 Industry Overview

5.1.4 Government Role

5.1.5 Bio-clusters

5.1.6 Opportunities & Challenges

5.1.6.1 Opportunities

5.1.6.1.1 Pharmaceutical Sector

5.1.6.1.2 Medical Devices Market

5.1.6.1.3 In Vitro Diagnostics Market

5.1.6.1.4 Agriculture

5.1.6.1.5 Food & Bioprocessing Industry

5.1.6.1.6 Biotools Market

5.1.6.1.7 Bioinformatics

5.1.6.1.8 Environment Market

5.1.6.2 Challenges

5.1.6.2.1 Heavy Burden on the Government

5.1.6.2.2 Lack of Bioventures in Japan

5.1.6.2.3 Lack of Integration between Academic Research & Industry

5.1.6.2.4 Regulatory System

5.1.6.2.5 Laggard in Certain Areas

5.1.7 Future Outlook (2007-2009)

5.2 China

5.2.1 Market Overview

5.2.2 Market Segmentation

5.2.3 Industry Overview

5.2.4 Government Role

5.2.5 Bio-clusters

5.2.6 Opportunities & Challenges

5.2.6.1 Opportunities

5.2.6.1.1 Biopharmaceuticals

5.2.6.1.2 New Drug Development

5.2.6.1.3 Lab Supplies

5.2.6.1.4 Bio-services

5.2.6.1.5 Chemicals & Enzymes

5.2.6.1.6 Agri & Aquaculture

5.2.6.1.7 Environmental Products & Services

5.2.6.2 Challenges

5.2.6.2.1 Overdependence on the Government

5.2.6.2.2 Lack of Coordination between Divisions & Researchers

5.2.6.2.3 Long-term Acceptance of Biotechnology Products

5.2.6.2.4 Regulations Restricting Foreign Investment

5.2.6.2.5 Intellectual Property & Underdeveloped Capital Market

5.2.6.2.6 Lack of Management & Investor Seasoning

5.2.7 Future Outlook (2007-2009)

5.3 India

5.3.1 Market Analysis

5.3.2 Market Segmentation

5.3.3 Government Role

5.3.4 Bio-clusters

5.3.5 Opportunities & Challenges

5.3.5.1 Opportunities

5.3.5.1.1 Outsourcing of Preliminary Research

5.3.5.1.2 Off-patent Drug

5.3.5.1.3 Clinical Trial Market

5.3.5.1.4 Bioinformatics

5.3.5.1.5 Stem Cell Research

5.3.5.1.6 Agricultural Biotechnology

5.3.5.1.7 Biofuel

5.3.5.1.8 Biofertilizers/Biopesticides

5.3.5.2 Challenges

5.3.5.2.1 Lack of IPR (Intellectual Property Rights) Regime

5.3.5.2.2 Time to Market

5.3.5.2.3 Seed Funding

5.3.5.2.4 Synergy between Stakeholders

5.3.5.2.5 High Innovative Drug Cost

5.3.5.2.6 Regulatory Issues

5.3.6 Future Outlook (2007-2010)

5.4 Australia

5.4.1 Market Analysis

5.4.2 Market Segmentation

5.4.3 Industry Overview

5.4.4 Government Role

5.4.5 Bio-clusters

5.4.6 Opportunities & Challenges

5.4.6.1 Opportunities

5.4.6.1.1 Agrobiotechnology

5.4.6.1.2 Health

5.4.6.1.3 Environmental Biotechnology

5.4.6.1.4 Industrial Biotechnology

5.4.6.1.5 Stem Cell Research

5.4.6.2 Challenges

5.4.6.2.1 Lack of Commercial Skills

5.4.6.2.2 Lack of Commercial Finesse

5.4.6.2.3 Inability to Market a Product

5.4.6.2.4 Ethical & Consumer Issues

5.4.6.2.5 Cash

5.4.7 Future Outlook (2007-2010)

5.5 Taiwan

5.5.1 Market Analysis

5.5.2 Market Segmentation

5.5.3 Market Overview

5.5.4 Government Role

5.5.5 Bio-clusters

5.5.6 Opportunities & Challenges

5.5.6.1 Opportunities

5.5.6.1.1 Bioinformatics

5.5.6.1.2 Pharmaceuticals

5.5.6.1.3 Medical Devices

5.5.6.1.4 New Emerging Biotech Sectors

5.5.6.2 Challenges

5.5.6.2.1 Inadequate Funding for Research

5.5.6.2.2 Legislations of Certain Laws

5.5.6.2.3 Weak Connection between Laboratories & Factories

5.5.6.2.4 Limited Competition Ability

5.5.6.2.5 Inadequate Understanding of Biotechnology

5.5.6.2.6 Traditional Nursery Companies and GMO Business

5.5.6.2.7 Need for International Co-operation

5.5.7 Future Outlook (2007-2010)

5.6 South Korea

5.6.1 Market Analysis

5.6.2 Market Segmentation

5.6.3 Market Overview

5.6.4 Government Role

5.6.5 Bio-clusters

5.6.6 Opportunities & Challenges

5.6.6.1 Opportunities

5.6.6.1.1 International Markets for Drugs

5.6.6.1.2 Embryo Cell Cloning & Human Stem Cell Development

5.6.6.1.3 Developing a Large Pool of Bio-ventures

5.6.6.1.4 Bioinformatics

5.6.6.1.5 Environmental Biotechnology

5.6.6.1.6 Nanobiotechnology

5.6.6.2 Challenges

5.6.6.2.1 Dr. Hwang Controversy

5.6.6.2.2 Non-Tariff Barriers to Potential Market Entrants

5.6.6.2.3 Bioethics & Biosafety

5.6.6.2.4 Complicated Distribution Channels

5.6.6.2.5 Lack of Clinical Testing Capabilities

5.6.6.2.6 International Patents

5.6.6.2.7 Weak Knowledge Base

5.6.6.2.8 Inadequate Local Venture Capital or Funds

5.6.7 Future Outlook (2007-2010)

5.7 New Zealand

5.7.1 Market Analysis

5.7.2 Market Segmentation

5.7.3 Market Overview

5.7.4 Government Role

5.7.5 Bio-clusters

5.7.6 Opportunities & Challenges

5.7.6.1 Opportunities

5.7.6.1.1 Agriculture

5.7.6.1.2 Increased Venture Capital (VC) & Private Equity (PE) Funding

5.7.6.1.3 Environment Biotechnology

5.7.6.1.4 Industrial Biotechnology

5.7.6.1.5 Nanotechnology

5.7.6.2 Challenges

5.7.6.2.1 Lack of Support for a Long-term Direction

5.7.6.2.2 Lack of Human Resource

5.7.6.2.3 Commercial Vulnerability

5.7.6.2.4 Reliance on International Companies for Technologies

5.7.6.2.5 Negative Perceptions held by Potential Overseas Investors

5.7.7 Future Outlook (2007-2010)

5.8 Singapore

5.8.1 Market Analysis

5.8.2 Market Overview

5.8.3 Government Role

5.8.4 Bio-clusters

5.8.5 Opportunities & Challenges

5.8.5.1 Opportunities

5.8.5.1.1 Biopharmaceuticals

5.8.5.1.2 Clinical Trials Hub

5.8.5.1.3 Bioinformatics

5.8.5.1.4 Nanotechnology

5.8.5.1.5 Stem Cell Research

5.8.5.1.6 Enabling Technologies

5.8.5.1.7 Intellectual Property

5.8.5.2 Challenges

5.8.5.2.1 Venture Funding

5.8.5.2.2 Human Resources

5.8.5.2.3 Low Rate of Survival for Biotechnology Startups

5.8.5.2.4 Lack of Understanding of Life Sciences Ingredients

5.8.5.2.5 Inability to Respond to Changes in the Industry

5.8.6 Future Outlook (2007-2009)

6. Industry Analysis

6.1 Key Driving Forces

6.1.1 Strong G4Government Support

6.1.2 Human Resources

6.1.3 Bio-diversity

6.1.4 Infrastructure

6.1.5 Low Cost

6.2 Opportunities

6.2.1 Contract Research/Manufacturing

6.2.2 Vaccines

6.2.3 Generics

6.2.4 Biofuel

6.2.5 Stem Cell Research

6.2.6 Nanotechnology

6.2.7 Bioremediation

6.2.8 Bioinformatics

6.3 Challenges

6.3.1 Lack of IPR Regime

6.3.2 Lack of Private Participation

6.3.3 Lack of Bioventures

6.3.4 Seed Funding

6.3.5 Inability to Take a Product from Invention to the Market

6.3.6 Ethical & Safety Issues

6.4 Future Outlook - 2009

6.4.1 Increased Government Support

6.4.2 Role of Private Sector

6.4.3 Improved Intellectual Property Regime

6.4.4 Mergers & Acquisitions

6.4.5 Infrastructure Improvement

6.4.6 Sustained Growth in Revenues till 2009

6.4.7 Japan, China, & Taiwan to Dominate the Market

7. Competitive Landscape

7.1 Invitrogen Corporation

7.2 Takara Holdings, Inc.

7.3 CSL Limited

7.4 Biota Holdings Limited

7.5 GlaxoSmithKline Plc

List of Figures:

Figure 3-1: Worldwide - Biotechnology Market (in Billion US$), 2001-2006E

Figure 3-2: Worldwide - Biotechnology Market Share by Segment (%), 2005

Figure 3-3: Worldwide - Forecast for Biotechnology Market (in Billion US$), 2007-2010

Figure 4-1: Asia-Pacific - Biotechnology Market (in Billion US$), 2004-2006E

Figure 4-2: Asia-Pacific - Biotechnology Market Segmentation by Country (%), 2006E

Figure 4-3: Asia-Pacific - Biotechnology Market by Segment (%), 2004

Figure 5-1: Japan - Biotechnology Market (in Billion US$), 2000-2006E

Figure 5-2: Japan - Biotechnology Market by Segment (%), 2004

Figure 5-3: Japan - Geographical Distribution of Bio-Clusters

Figure 5-4: Japan - Pharmaceutical Market (in Billion US$), 2003-2006

Figure 5-5: Japan - Medical Devices Market (in Billion US$), 2001, 2003 & 2006

Figure 5-6: Japan - In Vitro Diagnostics Market (in Million Yen), 2000-2004 & 2006E

Figure 5-7: Japan - Forecast for Biotechnology Market (in Billion US$), 2007-2009

Figure 5-8: China - Biotechnology Market (in Billion US$), 2000-2006E

Figure 5-9: China - Biotechnology Market by Segment (%), 2004

Figure 5-10: China - Investment in Biotechnology by Government (in Billion US$), 2001, 2005 & 2010F

Figure 5-11: China - Biopharmaceuticals Market (in Billion US$), 2005, 2006E & 2010

Figure 5-12: China - Forecast for Biotechnology Market (in Billion US$), 2007-2009

Figure 5-13: India - Biotechnology Market (in Million US$), 2002-2006E

Figure 5-14: India - Biotechnology Market by Segment (%), 2005

Figure 5-15: India - Clinical Trials Market (in Million US$), 2006 & 2010F

Figure 5-16: India - Forecast for Stem Cell Market (in Million US$), 2010-2015

Figure 5-17: India - Forecast for Biotechnology Market (in Billion US$), 2007-2010

Figure 5-18: Australia - Biotechnology Market (in Million AU$), 1998, 2002 & 2006E

Figure 5-19: Australia - Biotechnology Market by Segment (%), 2003

Figure 5-20: Australia - Geographical Distribution of Bio-clusters

Figure 5-21: Worldwide - Industrial Biotech Applications in the Chemical Industry (in Billion US$), 2005 & 2010F

Figure 5-22: Australia - Forecast for Biotechnology Market (in Million AU$), 2007-2010

Figure 5-23: Taiwan - Biotechnology Market (in Billion US$), 2004-2006E

Figure 5-24: Taiwan - Biotechnology Market Share by Segment (%), 2005

Figure 5-25: Taiwan - Biomedical Industry Production (in Billion US$), 2004 & 2005

Figure 5-26: Taiwan - Forecast for Biotechnology Market (in Billion US$), 2007-2010

Figure 5-27: South Korea - Biotechnology Market (in Billion US$), 2002-2004 & 2006E

Figure 5-28: South Korea - Biotechnology Market by Segment (%), 2004

Figure 5-29: South Korea - Geographical Distribution of Bio-clusters

Figure 5-30: South Korea - Number of Bio-Ventures (1999 & 2003)

Figure 5-31: South Korea - Forecast for Biotechnology Market (in Billion US$), 2007-2010

Figure 5-32: New Zealand - Biotechnology Market (in Million NZ$), 1999, 2004, 2005 & 2006E

Figure 5-33: New Zealand - Biotechnology Market by Segment (%), 2005

Figure 5-34: New Zealand - Geographical Distribution of Bio-clusters

Figure 5-35: New Zealand - Venture Capital/Private Equity Funding (in Million NZ$), 2004 & 2005

Figure 5-36: New Zealand - Number of Venture Capital/Private Equity Deals (2004 & 2005)

Figure 5-37: New Zealand - Forecast for Biotechnology Market (in Million NZ$), 2007-2010

Figure 5-38: Singapore - Biomedical Science Market (in Billion US$), 2003-2006

Figure 5-39: Singapore - Biotechnology Market (in Million US$), 2005 & 2006E

Figure 5-40: Singapore - Forecast for Biotechnology Market (in Million US$), 2007-2009

Figure 5-41: Singapore - Forecast for Biomedical Science Industry (in Billion US$), 2007, 2009, 2012 & 2015

Figure 6-1: South Korea - Budget Allocated for Research & Development (in Billion US$), 2005 & 2006

Figure 6-2: China, India, Europe & US - Number of Engineers Passed Out (in Thousand), 2005

Figure 6-3: US & India - Trials for Standard Drugs (in Million US$), 2004

Figure 6-4: India - Contract Research Market (in Million US$), 2005-2009F

Figure 6-5: India & China - Vaccine Market (in Million US$), 2005, 2006E & 2008

Figure 6-6: Worldwide - Stem Cell Products & Services Market (in Billion US$), 2005 & 2010F

Figure 6-7: Worldwide - Nano Technology Applications in Life Sciences (in Billion US$), 2005 & 2010F

Figure 6-8: Asia-Pacific - Bioinformatics Market (in Million US$), 2002-2006E & 2010F

Figure 6-9: Singapore - Budget Allocation for Research & Development (in Billion US$), 2001-2005 & 2006-2010

Figure 6-10: India - Number of Biotech Parks (2005 & 2008-09F)

Figure 6-11: Asia-Pacific - Forecast for Biotechnology Market (in Billion US$), 2007-2009

Figure 6-12: Asia-Pacific - Forecast for Biotechnology Market Segmentation by Country (%), 2009

List of Tables:

Table 3-1: Asia-Pacific - Mergers & Acquisitions (2006-07)

Table 5-1: Japan - Recent Biotechnology Regulations & Entry of Foreign Biotechnology Companies (1975 to 2005)

Table 7-1: Invitrogen Corporation - Financial Overview (in Million US$), 2004-2006

Table 7-2: Takara Holdings, Inc. - Financial Overview (in Thousand JPY), 2004-2006

Table 7-3: CSL Limited - Financial Overview (in Thousand AU$), 2004-2006

Table 7-4: Biota Holdings Limited - Financial Overview (in Thousand AU$), 2004-2006

Table 7-5: GlaxoSmithKline Plc - Financial Overview (in Million US$), 2004-2006

Abstract

• Growing at an estimated CAGR of 11.23% between 2004 and 2006, the expected value of Asia-Pacific Biotechnology market by 2006 end is more than US$ 39.16 Billion.
• Japan, China, and Taiwan are the largest Biotechnology markets in the Asia-Pacific region that had a combined market share of nearly 76% in 2006.
• The Asia-pacific region will emerge as a key destination for clinical trials & stem cell research.
• Biotechnology will play an important role in agriculture sector by developing large number of genetically modified (GM) crops.
• Biopharma industry, comprising of vaccines, therapeutics, diagonostics and other products, will emerge as a major segment of the Asia-Pacific Biotech industry.
• The Biotechnology industry in the Asia-pacific region is largely dependent on the government with very little private participation in most of the countries.
• Lack of venture funding remains a major challenge for Asia-Pacific Biotechnology companies.
• The Contract Research industry in India could reach as high as US$ 270 Million by 2009.
• The Japanese Government, which was earlier accused of shielding its domestic companies, has now opened its doors for foreign investment.
• Opaque government policies and regulations in China are acting as a major hurdle for foreign participation in the biotechnology market.

• What are the market trends in the Asia-Pacific Biotechnology industry?
• A insight into the Biotechnology industries of Japan, China, India, Korea, Australia, Taiwan, New Zealand, and Singapore.
• The role played by the goverments in Asia-Pacific in promoting their respective Biotech industries.
• An overview of Bioclusters in the Asia-Pacific Biotechnology industry.
• Key sectors in the Asia-Pacific biotechnology industry.
• Course of market growth for the next 5 years.
• Opportunities that can be leveraged by the Asia-Pacific Biotechnology industry.
• Forces that are working in favor of Asia-Pacific Biotechnology industry.
• Issues confronted by the Asia-Pacific Biotechnology industry.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.